Duration of antifungal treatment and development of delayed complications in patients with candidaemia
- PMID: 12582743
- DOI: 10.1007/s10096-002-0854-6
Duration of antifungal treatment and development of delayed complications in patients with candidaemia
Abstract
The optimal duration of antifungal treatment of candidaemia is unknown. Prolonged treatment has been advocated to prevent late-onset complications caused by metastatic infectious foci. To evaluate the relationship between duration of antifungal therapy and the development of delayed complications in patients with candidaemia, a retrospective descriptive study was performed in a tertiary care centre. The study included 180 consecutive patients with candidaemia identified by at least one positive blood culture. Development of late-onset complications of candidaemia during long-term follow-up was monitored. Of the patients treated with antifungal agents, 55% completed treatment without apparent complications, 33% died during therapy, 12% developed disseminated disease and one patient continues to receive ongoing treatment. Of the 81 patients who completed treatment as scheduled, 25% received treatment for less than 2 weeks, 31% for 2-4 weeks and 38% for more than 4 weeks; duration of therapy was unknown in 6%. Only three (2%) patients developed delayed complications; in these patients, the duration of antifungal treatment had been 3 weeks, 5 weeks and 22 weeks, respectively. In conclusion, despite theoretical concerns, there seems to be no correlation between the duration of antifungal treatment and the development of late complications in patients with candidaemia. This suggests that treatment of 2 weeks or less may be sufficient, provided the initial response to therapy is favourable.
Similar articles
-
Caspofungin for the treatment of candidaemia in patients with haematological malignancies.Clin Microbiol Infect. 2010 Mar;16(3):298-301. doi: 10.1111/j.1469-0691.2009.02832.x. Epub 2009 Jun 22. Clin Microbiol Infect. 2010. PMID: 19549221
-
Risk factors and outcome for nosocomial breakthrough candidaemia.J Infect. 2006 Mar;52(3):216-22. doi: 10.1016/j.jinf.2005.04.020. Epub 2005 Jun 3. J Infect. 2006. PMID: 15936825
-
Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia.Diagn Microbiol Infect Dis. 2004 Oct;50(2):119-24. doi: 10.1016/j.diagmicrobio.2004.06.004. Diagn Microbiol Infect Dis. 2004. PMID: 15474321
-
Treatment options in candidaemia.Mycoses. 2007;50 Suppl 1:44-9. doi: 10.1111/j.1439-0507.2007.01379.x. Mycoses. 2007. PMID: 17394609 Review.
-
New antifungal agents for the treatment of candidaemia.Int J Antimicrob Agents. 2010 Dec;36 Suppl 2:S63-9. doi: 10.1016/j.ijantimicag.2010.11.007. Epub 2010 Dec 3. Int J Antimicrob Agents. 2010. PMID: 21129925 Review.
Cited by
-
Invasive fungal infections: the challenge continues.Drugs. 2009;69 Suppl 1:65-73. doi: 10.2165/11315530-000000000-00000. Drugs. 2009. PMID: 19877737 Review.
-
Management bundles for candidaemia: the impact of compliance on clinical outcomes.J Antimicrob Chemother. 2015 Feb;70(2):587-93. doi: 10.1093/jac/dku414. Epub 2014 Oct 17. J Antimicrob Chemother. 2015. PMID: 25326087 Free PMC article.
-
Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study.Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):317-22. doi: 10.1007/s10096-004-1103-y. Epub 2004 Mar 17. Eur J Clin Microbiol Infect Dis. 2004. PMID: 15029512
-
Infections fongiques des brûlé : revue.Ann Burns Fire Disasters. 2015 Mar 31;28(1):21-8. Ann Burns Fire Disasters. 2015. PMID: 26668558 Free PMC article. French.
-
Treatment of Invasive Candidiasis: A Narrative Review.J Fungi (Basel). 2018 Aug 16;4(3):97. doi: 10.3390/jof4030097. J Fungi (Basel). 2018. PMID: 30115843 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical